CAMBRIA 1: camizestrant ER+/HER2- early breast cancer

CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancerПодробнее

SERENA-2: camizestrant vs fulvestrant in post-menopausal women with advanced ER+/HER- breast cancerПодробнее

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant for advanced ER+ HER2- breast cancerПодробнее

Breast Cancer Breakthroughs: New oral SERDs being tested in early breast cancerПодробнее

First-line camizestrant for ER+/HER2- advanced breast cancerПодробнее

The CAMBRIA-2 Clinical Trial - Wendy RollsПодробнее

The CAMBRIA-2 Clinical Trial AnimationПодробнее

Camizestrant may be superior to fulvestrant in patients with HR-positive, HER2-negative BCПодробнее

The CAMBRIA-2 Clinical TrialПодробнее

Case 1: Approach to Early Stage, HER2+ Breast CancerПодробнее

HER2DX risk-score in early-stage HER2-positive breast cancerПодробнее

Early Stage Breast Cancer | 2022 OneOncology ConferenceПодробнее

ER degrader safe, with signs of antitumour activity against ER-positive breast cancerПодробнее

Diagnosis of HER2+/ER- Early Breast CancerПодробнее

Treatment for Early-Stage ER+ Breast CancerПодробнее

Case 1: Treatment for Early-Stage HER2+ Breast CancerПодробнее

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast CancerПодробнее

New Breast Cancer Clinical Trial: Imlunestrant for Breast CancerПодробнее